Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
bullish
United States Health Care
Biopharma Week in Review - Vaccine Advisory Board Overhaul Sudden but Not Surprising
Thematic (Sector/Industry)
189 Views
18 Jun 2025 11:38
Issuer-paid
Pharma benefited from some defensive sector rotation, led by the big obesity duo, LLY and NVO, ahead of this week’s major diabetes conference (ADA 2025).
What is covered in the Full Insight:
Pharma Sector Rotation
Vaccine Policy Overhaul
Drug Pricing and MFN Update
Key Company Developments
Market Reactions and Outlook
SUMMARY
(Sign Up to Access)
Full Insight
(Paid Plans Only, 12-minute read)
Related Insights
More »
Gilead Sciences: Cell Therapy Adoption & Expansion to Strengthen Its Competitive Position n Its Domain!
Gilead Sciences: Pipeline Progress & Regulatory Milestones As A Pivotal Growth Lever!
How Gilead Sciences' HIV & Other Innovations Are Set to Capture Untapped Markets & Drive Massive Growth! - Major Drivers
Gilead Sciences: Innovations in Oncology & Cellular Therapy Along With Anti-Viral Focus! - Major Drivers
Gilead Sciences: Acquisition of CymaBay Therapeutics Enhancing Liver Disease Portfolio & 6 Major Drivers
Trending Collections
More »
Japan
Event-Driven
Equity Bottom-Up
Sell / Short Ideas
India
Asia Event-Driven
Asia ECM
South Korea
Unpaywalled Insights
Philippines
Trending Insights
More »
Dickson Concepts (113 HK): A Necessary HK Arbageddon
HEW: Inflation Persists, But Cuts Loom
NSDL Vs CDSL: A Bottom-Up Comparison
[Japan Activism] Mitsui Matsushima (1518 JP) Buyback Tender - Surprising Results and Implications
TSMC (2330.TT) Outlook Post Strong Q2: Our Model Says "EXTREME OVERBOUGHT CONDITION"
Top Unpaywalled Insights
More »
[IO Technicals 2025/29] Near Term Bullish Trend to Persist
Veon's (Nasdaq: VEON) Subsidiary Kyivstar Eyes Nasdaq Listing
Reimagining Venture Capital Through Impact Investing | Chris Maher on Disability Innovation
[IO Technicals 2025/28] Bullish Momentum Intensifies
Mid-Year Themes Review - Part II
Discussions
(Paid Plans Only)
Insight Stream
Biopharma Week in Review - Vaccine Advisory Board Overhaul Sudden but Not Surprising
18 Jun 2025
Top
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.54.8
x